Every one of those 1 sits in a single category, fda-approval. Of the tracked stories, 1 of 1 also mention Solius Labs, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention UVB light therapy, all published on June 18, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about UVB light therapy
Every one of those 1 sits in a single category, fda-approval. Of the tracked stories, 1 of 1 also mention Solius Labs, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention UVB light therapy, all published on June 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering UVB light therapy. Shared-story counts are live from our verified record — not editorial picks.
The FDA has established a novel product code for Solius Pro, an over-the-counter UVB light therapy device that claims to deliver biological benefits of sunlight with dramatically reduced risk. The move signals regulatory recognition of personalized home phototherapy as a distinct category.